G Hoffmann

No ORCID on file · 6 papers in corpus · active 1990-1996

Study types

  • article 4
  • book-chapter 2

Condition tags

  • endometriosis 4
  • dysmenorrhea 3
  • infertility 3
  • dyspareunia 3
article 1996
[Long-term observations of the extent and reversibility of bone demineralization after leuprorelin acetate depot therapy].
Zentralblatt fur Gynakologie

Therapy of endometriosis with a GnRH-agonist (Leuprorelin) demonstrated a good therapeutical efficiency. As a side effect it had a significant negative impact on trabecular bone mass (non significant on cortical bone) as measured by DXA. Ri…

article 1996
[Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)].
Zentralblatt fur Gynakologie

In a previous study 198 patients with histologically confirmed endometriosis underwent a "three-step" therapy, where surgical removal of endometriosis implants was followed by a 6 months treatment with 3.75 mg leuprorelinacetate depot as mo…

book-chapter 1995
Dienogest: Bindungsstudien an verschiedenen Rezeptor- und Serumproteinen
·doi:10.1515/9783110813210-013
book-chapter 1995
Dienogest: Bindungsstudien an verschiedenen Rezeptor- und Serumproteinen
·doi:10.1515/9783112422168-013
article 1992
Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study.
Clinical therapeutics

During the past decade, the development of various gonadotrophin-releasing hormone (Gn-RH) agonists, which induce reversible hypo-oestrogenism has opened a new area in the medical management of endometriosis. In an open, multicentre phase I…

article 1990
[GnRH-agonists in the therapy of endometriosis].
Therapeutische Umschau. Revue therapeutique

Repeated application of GnRH agonists causes a reversible suppression of ovarian function. Suppression on estrogen release is the fundamental idea of this hormonal therapy of endometriosis. We treated twelve patients with histologically pro…